In Nigeria, EGPAF is filling a critical niche in the HIV response for children, adolescents and pregnant women through: Piloting innovative service delivery models at the facility level, making HIV prevention and treatment services more accessible and effective; building high-impact partnerships to better link HIV services across the community and facility levels; growing specialized clinical capacity in pediatric HIV, to manage complex cases, and increase access to additional HIV treatment regimens; and partnering with federal and state health leaders to advocate for children and families living with HIV. Our work alongside Nigeria’s Ministry of Health, local organizations and the country’s health facilities will continue to grow under our Delivering Technical Assistance (Project DELTA 2), our ViiV Breakthrough and our New Horizons Projects (see below).
To learn more about our TA work, please click here.
Projects
Open | 2023 - 2026
Pediatric Breakthrough Partnership
This project is funded by ViiV.
Open | 2024
New Horizons Collaborative
Since 2014, the New Horizons Collaborative, funded by Johnson and Johnson, works with 10 countries in sub-Saharan Africa to advance high-quality, sustainable care for children and adolescents living with HIV.
The New Horizons Collaborative:
Decentralizes decision-making in pediatric and adolescent HIV care and treatment
Develops data-tracking systems for children and adolescents
Shares lessons learned with the community and global stakeholders
J&J donates Darunavir and Etravirine to participating countries for 2nd and 3rd line ART
Strengthens health system capacity for treatment failure management
The 2023 Treatment Failure Cascade for 7 New Horizons Countries
New Horizons at Work
These toolkits were designed to fill gaps identified by the collaborative in treatment failure management, disclosure, and transition of care. Please feel free to download and use them! Translations in French and Portuguese are available for the Disclosure Toolkit, and the Treatment Failure Management Toolkit is available in French and English.
This project improves sustainable ART service delivery for children and confronts challenges that adolescents face around disclosure, adherence, and psychosocial support.
The Pediatric HIV Breakthrough Partnership aims to end pediatric AIDS in priority locations through developing a sustainable and replicable-quality package of interventions that is informed by the pediatric HIV service delivery tool developed by UNAIDS titled “Improving HIV Service Delivery for Infants, Children and Adolescents.”
Closed | 2014-Present
The New Horizons Advancing Pediatric and Adolescent HIV Treatment Collaborative Initiative, Nigeria
HIV has shifted in its definition from a fatal disease to a chronic illness thanks to effective treatment regimens. Long-term treatment, however effective, can become less or ineffective over a lifetime, especially when treatment interruptions take place. With more and more children and adolescents diagnosed and enrolled on lifelong ART, demand for second- and third-line treatment is expected to increase in coming years. Prevention and management of treatment failure in children and adolescents living with HIV must be prioritized to achieve and maintain viral suppression and prevent drug resistance in a population suffering from increasing HIV-related morbidity and mortality.
In 2022, the NH will transition to a new phase of New Horizons 2.0, EGPAF as a key implementing partner along with other current partners including Partnership for Supply Chain Management, Imperial Logistics, CIPHER Paediatric HIV Matters, Right to Care, and the Paediatric European Network for Treatment of AIDS.
Closed | 2021
New Horizons Project 2021
In 2021, the NH will transition to a new phase of New Horizons 2.0, EGPAF as a key implementing partner along with other current partners including Partnership for Supply Chain Management, Imperial Logistics, CIPHER Paediatric HIV Matters, Right to Care, and the Paediatric European Network for Treatment of AIDS.
DELTA2 is a five-year, U.S. Centers for Disease Control and Prevention (CDC)-funded cooperative agreement implemented by EGPAF.
Open | 2019 - 2023
New Horizons Study 2019 – 2023
Demographic Clinical, and Laboratory Characteristics and Outcomes of Pediatric Patients Who Ever Received Etravirine and/or Darunavir
The current activity proposes to collect cross-sectional demographic and clinical data at baseline and every six months for patients receiving DRV and/or ETR across participating New Horizons countries. This activity will comprise data abstraction of a key demographic, clinical, laboratory and case history indicators and outcomes on each patient who ever received DRV and/or ETR.
Since 2014, the New Horizons Collaborative, funded by Johnson and Johnson, works with 
